Targeting Free Radicals in Oxidative Stress-Related Human Diseases

Behrens, 2009, A common biological mechanism in cancer and Alzheimer’s disease?, Curr. Alzheimer Res., 6, 196, 10.2174/156720509788486608 Driver, 2012, Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study, BMJ, 344, e1442, 10.1136/bmj.e1442 Plun-Favreau, 2010, Cancer and neurodegeneration: between the devil and the deep blue sea, PLoS Genet., 6, 1, 10.1371/journal.pgen.1001257 Firuzi, 2011, Antioxidant therapy: current status and future prospects, Curr. Med. Chem., 18, 3871, 10.2174/092986711803414368 Valko, 2007, Free radicals and antioxidants in normal physiological functions and human disease, Int. J. Biochem. Cell Biol., 39, 44, 10.1016/j.biocel.2006.07.001 Wu, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol. Sci., 36, 422, 10.1016/j.tips.2015.04.005 Halliwell, 2011, Free radicals and antioxidants – Quo vadis?, Trends Pharmacol. Sci., 32, 125, 10.1016/j.tips.2010.12.002 Lehoux, 2006, Redox signalling in vascular responses to shear and stretch, Cardiovasc. Res., 71, 269, 10.1016/j.cardiores.2006.05.008 Gorrini, 2013, Modulation of oxidative stress as an anticancer strategy, Nat. Rev. Drug Discov., 12, 931, 10.1038/nrd4002 Weinstein, 2008, Oncogene addiction, Cancer Res., 68, 3077, 10.1158/0008-5472.CAN-07-3293 Trachootham, 2009, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?, Nat. Rev. Drug Discov., 8, 579, 10.1038/nrd2803 Jones, 2009, Tumor suppressors and cell metabolism: a recipe for cancer growth Tumor suppressors and cell metabolism: a recipe for cancer growth, Genes Dev., 8, 537, 10.1101/gad.1756509 Halliwell, 2007, Oxidative stress and cancer: have we moved forward?, Biochem. J., 401, 1, 10.1042/BJ20061131 Blot, 1993, Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population, J. Natl. Cancer Inst., 85, 1483, 10.1093/jnci/85.18.1483 Zhang, 2012, Vitamin intake and liver cancer risk: a report from two cohort studies in China, J. Natl. Cancer Inst., 104, 1173, 10.1093/jnci/djs277 The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers, N. Engl. J. Med., 330, 1029, 10.1056/NEJM199404143301501 Klein, 2011, Vitamin E and the risk of prostate cancer, JAMA, 306, 1549, 10.1001/jama.2011.1437 Carr, 1999, Does vitamin C act as a pro-oxidant under physiological conditions?, FASEB J., 13, 1007, 10.1096/fasebj.13.9.1007 Bast, 2013, Ten misconceptions about antioxidants, Trends Pharmacol. Sci., 34, 430, 10.1016/j.tips.2013.05.010 Richelle, 2006, Skin bioavailability of dietary vitamin E, carotenoids, polyphenols, vitamin C, zinc and selenium, Br. J. Nutr., 96, 227, 10.1079/BJN20061817 Halliwell, 1996, Vitamin C: antioxidant or prooxidant in vivo?, Free Radic. Res., 25, 439, 10.3109/10715769609149066 Halliwell, 2007 Lambeth, 2007, Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy, Free Radic. Biol. Med., 43, 332, 10.1016/j.freeradbiomed.2007.03.027 Imlay, 2008, Cellular defenses against superoxide and hydrogen peroxide, Annu. Rev. Biochem., 77, 755, 10.1146/annurev.biochem.77.061606.161055 Unger, 2015, Prediction of individual response to anticancer therapy: historical and future perspectives, Cell. Mol. Life Sci., 72, 729, 10.1007/s00018-014-1772-3 Halliwell, 2008, Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies?, Arch. Biochem. Biophys., 476, 107, 10.1016/j.abb.2008.01.028 Liou, 2010, Reactive oxygen species in cancer, Free Radic. Res., 44, 479, 10.3109/10715761003667554 Conklin, 2004, Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness, Integr. Cancer Ther., 3, 294, 10.1177/1534735404270335 Barrera, 2012, Oxidative stress and lipid peroxidation products in cancer progression and therapy, ISRN Oncol., 2012, 137289 Kummar, 2012, Advances in using PARP inhibitors to treat cancer, BMC Med., 10, 25, 10.1186/1741-7015-10-25 Kaufmann, 2000, Induction of apoptosis by cancer chemotherapy, Exp. Cell Res., 256, 42, 10.1006/excr.2000.4838 Zhang, 2011, Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells, Cancer Lett., 313, 201, 10.1016/j.canlet.2011.09.005 Hao, 2010, HSP90 and its inhibitors, Oncol. Rep., 23, 223 Neckers, 2012, Hsp90 molecular chaperone inhibitors: are we there yet?, Clin. Cancer Res., 18, 64, 10.1158/1078-0432.CCR-11-1000 Tai, 2012, Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells, Exp. Ther. Med., 4, 291, 10.3892/etm.2012.591 Griffith, 1982, Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis, J. Biol. Chem., 257, 13704, 10.1016/S0021-9258(18)33504-X Ishimoto, 2011, CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc− and thereby promotes tumor growth, Cancer Cell, 19, 387, 10.1016/j.ccr.2011.01.038 Lo, 2010, Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer, Curr. Oncol., 17, 9, 10.3747/co.v17i3.485 Montero, 2012, Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer, Breast Cancer Res. Treat., 132, 215, 10.1007/s10549-011-1889-0 Fan, 2014, Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo, Cell Death Dis., 5, e1191, 10.1038/cddis.2014.132 Kiebala, 2015, Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach, Exp. Hematol., 43, 89, 10.1016/j.exphem.2014.10.004 Marzano, 2007, Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells, Free Radic. Biol. Med., 42, 872, 10.1016/j.freeradbiomed.2006.12.021 Wei, 2008, Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies, Proc. Natl. Acad. Sci. U. S. A., 105, 19738, 10.1073/pnas.0810676105 Wei, 2011, Sulfiredoxin–peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling, Proc. Natl. Acad. Sci U. S. A., 108, 7004, 10.1073/pnas.1013012108 Jiang, 2015, Sulfiredoxin promotes colorectal cancer cell invasion and metastasis through a novel mechanism of enhancing EGFR signalling, Mol. Cancer Res., 13, 1554, 10.1158/1541-7786.MCR-15-0240 Vaughn, 2008, Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c, Nat. Cell Biol., 10, 1477, 10.1038/ncb1807 Simons, 2009, Glucose deprivation-induced metabolic oxidative stress and cancer therapy, J. Cancer Res. Ther., 5, S2 Patra, 2014, The pentose phosphate pathway and cancer, Trends Biochem. Sci., 39, 347, 10.1016/j.tibs.2014.06.005 Polimeni, 2011, Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity, Biochem. J., 439, 141, 10.1042/BJ20102016 Greenough, 2013, Metal dyshomeostasis and oxidative stress in Alzheimer’s disease, Neurochem. Int., 62, 540, 10.1016/j.neuint.2012.08.014 Kell, 2010, Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples, Arch. Toxicol., 84, 825, 10.1007/s00204-010-0577-x Butterfield, 2014, The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment, Free Radic. Biol. Med., 74, 157, 10.1016/j.freeradbiomed.2014.06.006 Korabecny, 2015, 7-methoxytacrine-p-anisidine hybrids as novel dual binding site acetylcholinesterase inhibitors for Alzheimer’s disease treatment, Molecules, 20, 22084, 10.3390/molecules201219836 Birks, 2006, Cholinesterase inhibitors for Alzheimer’s disease, Cochrane Database Syst. Rev., 2006, CD005593 Persson, 2014, Oxidative stress in Alzheimer’s disease: why did antioxidant therapy fail?, Oxid. Med. Cell. Longev., 2014, 427318, 10.1155/2014/427318 Hardy, 2002, The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 Akundi, 2011, Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice, PLoS One, 6, e16038, 10.1371/journal.pone.0016038 Cole, 2008, The role of amyloid precursor protein processing by BACE1, the β-secretase, in Alzheimer disease pathophysiology, J. Biol. Chem., 283, 29621, 10.1074/jbc.R800015200 Gu, 2010, Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases, Mol. Neurobiol., 41, 55, 10.1007/s12035-010-8113-9 Ayton, 2015, Biometals and their therapeutic implications in Alzheimer’s disease, Neurotherapeutics, 12, 109, 10.1007/s13311-014-0312-z Pretorius, 2013, A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy, Toxicol. Mech. Methods, 23, 352, 10.3109/15376516.2012.762082 Rajendran, 2009, A novel approach to the identification and quantitative elemental analysis of amyloid deposits – insights into the pathology of Alzheimer’s disease, Biochem. Biophys. Res. Commun., 382, 91, 10.1016/j.bbrc.2009.02.136 Prousek, 2007, Fenton chemistry in biology and medicine, Pure Appl. Chem., 79, 2325, 10.1351/pac200779122325 La Penna, 2013, Identifying, by first-principles simulations, Cu[amyloid-β] species making Fenton-type reactions in Alzheimer’s disease, J. Phys. Chem. B, 117, 16455, 10.1021/jp410046w Hatanaka, 2015, Differences in peripheral oxidative stress markers in Alzheimer’s disease, vascular dementia and mixed dementia patients, Geriatr. Gerontol. Int., 15, 53, 10.1111/ggi.12659 Butterfield, 2011, Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer’s disease, Free Radic. Res., 45, 59, 10.3109/10715762.2010.520014 Gertsik, 2015, Complex regulation of γ-secretase: from obligatory to modulatory subunits, Front. Aging Neurosci., 7, 342 Gwon, 2012, Oxidative lipid modification of nicastrin enhances amyloidogenic γ-secretase activity in Alzheimer’s disease, Aging Cell, 11, 559, 10.1111/j.1474-9726.2012.00817.x Dwyer, 2004, Homocysteine and Alzheimer’s disease: a modifiable risk?, Free Radic. Biol. Med., 36, 1471, 10.1016/j.freeradbiomed.2004.03.009 Cummings, 2016, Drug development in Alzheimer’s disease: the path to 2025, Alzheimers Res. Ther., 8, 39, 10.1186/s13195-016-0207-9 Godyń, 2016, Therapeutic strategies for Alzheimer’s disease in clinical trials, Pharmacol. Rep., 68, 127, 10.1016/j.pharep.2015.07.006 Galimberti, 2016, Old and new acetylcholinesterase inhibitors for Alzheimer’s disease, Expert Opin. Investig. Drugs, 25, 1181, 10.1080/13543784.2016.1216972 Brinkman, 1983, Measurement of cholinergic drug effects on memory in Alzheimer’s disease, Neurobiol. Aging, 4, 139, 10.1016/0197-4580(83)90038-6 Fusek, 1986, Anticholinesterase effects of 9-amino-7-methoxy-1,2,3,4-tetrahydroacridine, Act. Nerv. Super., 28, 327 Minarini, 2013, Multifunctional tacrine derivatives in Alzheimer’s disease, Curr. Top. Med. Chem., 13, 1771, 10.2174/15680266113139990136 Rodríguez-Franco, 2006, Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties, J. Med. Chem., 49, 459, 10.1021/jm050746d Sun, 2014, Syntheses of coumarin–tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase, Bioorg. Med. Chem., 22, 4784, 10.1016/j.bmc.2014.06.057 Nepovimova, 2015, Tacrine–trolox hybrids: a novel class of centrally active, nonhepatotoxic multi-target-directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity, J. Med. Chem., 58, 8985, 10.1021/acs.jmedchem.5b01325 Hamulakova, 2016, Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer’s disease using multifunctional tacrine-coumarin hybrid molecules, J. Inorg. Biochem., 161, 52, 10.1016/j.jinorgbio.2016.05.001 Richardson, 2004, Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions, Ann. N. Y. Acad. Sci., 1012, 326, 10.1196/annals.1306.026 Sharpe, 2011, Synthetic and natural products as iron chelators, Curr. Top. Med. Chem., 11, 591, 10.2174/156802611794785163 Richardson, 2009, 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity, J. Med. Chem., 52, 1459, 10.1021/jm801585u Whitnall, 2006, Iron: a new target for pharmacological intervention in neurodegenerative diseases, Semin. Pediatr. Neurol., 13, 186, 10.1016/j.spen.2006.08.008 Opazo, 2006, Radioiodinated clioquinol as a biomarker for β-amyloid: Zn2+ complexes in Alzheimer’s disease, Aging Cell, 5, 69, 10.1111/j.1474-9726.2006.00196.x Adlard, 2008, Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ, Neuron, 59, 43, 10.1016/j.neuron.2008.06.018 Crouch, 2011, The Alzheimer’s therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity, J. Neurochem., 119, 220, 10.1111/j.1471-4159.2011.07402.x White, 2006, Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity, J. Biol. Chem., 281, 17670, 10.1074/jbc.M602487200 Donnelly, 2008, Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-β peptide, J. Biol. Chem., 283, 4568, 10.1074/jbc.M705957200 Kaden, 2011, Disturbed copper bioavailability in Alzheimer’s disease, Int. J. Alzheimers. Dis., 2011, 345614 Kenche, 2011, Alzheimer’s disease & metals: therapeutic opportunities, Br. J. Pharmacol., 163, 211, 10.1111/j.1476-5381.2011.01221.x Schlief, 2006, Copper homeostasis in the CNS, Mol. Neurobiol., 33, 81, 10.1385/MN:33:2:81 Zheng, 2009, Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer’s therapy, J. Med. Chem., 52, 4095, 10.1021/jm900504c Amit, 2008, Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators, FASEB J., 22, 1296, 10.1096/fj.07-8627rev Arlt, 2012, Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer’s disease, Neurochem. Res., 37, 2706, 10.1007/s11064-012-0860-8 Baptista, 2014, Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer’s disease, ACS Chem. Neurosci., 5, 83, 10.1021/cn400213r Costa, 2016, Mechanisms of neuroprotection by quercetin: counteracting oxidative stress and more, Oxid. Med. Cell. Longev., 2016, 2986796, 10.1155/2016/2986796